142 related articles for article (PubMed ID: 38008504)
1. Risk factors of heavy uterine bleeding in patients with endometriosis and adenomyosis treated with dienogest.
Takagi H; Takakura M; Sasagawa T
Taiwan J Obstet Gynecol; 2023 Nov; 62(6):852-857. PubMed ID: 38008504
[TBL] [Abstract][Full Text] [Related]
2. Evaluating the safety of dienogest in women with adenomyosis: A retrospective analysis.
Ono N; Asano R; Nagai K; Sugo Y; Nakamura T; Miyagi E
J Obstet Gynaecol Res; 2021 Apr; 47(4):1433-1440. PubMed ID: 33590656
[TBL] [Abstract][Full Text] [Related]
3. [Efficacy of dienogest versus gonadotropin-releasing hormone agonist combined with dienogest sequential therapy in the treatment of adenomyosis].
Zhang HY; Zhu S; Xu W; Wang AQ; Wang XL
Zhonghua Fu Chan Ke Za Zhi; 2022 Nov; 57(11):856-863. PubMed ID: 36456483
[No Abstract] [Full Text] [Related]
4. Efficacy, Adverse Events, and Challenges of Dienogest in the Management of Symptomatic Adenomyosis: A Comparison with Different Hormonal Treatments.
Kobayashi H
Gynecol Obstet Invest; 2023; 88(2):71-80. PubMed ID: 36682346
[TBL] [Abstract][Full Text] [Related]
5. Heavy uterine bleeding in women with endometriosis and adenomyosis treated with dienogest.
Chou FW; Chang WH; Wang PH
Taiwan J Obstet Gynecol; 2024 Mar; 63(2):139-140. PubMed ID: 38485301
[No Abstract] [Full Text] [Related]
6. Risk factors of treatment discontinuation due to uterine bleeding in adenomyosis patients treated with dienogest.
Nagata C; Yanagida S; Okamoto A; Morikawa A; Sugimoto K; Okamoto S; Ochiai K; Tanaka T
J Obstet Gynaecol Res; 2012 Apr; 38(4):639-44. PubMed ID: 22413833
[TBL] [Abstract][Full Text] [Related]
7. Long-term treatment of dienogest with symptomatic adenomyosis: retrospective analysis of efficacy and safety in clinical practice.
Miao J; Lu J; Tang J; Lu P
Gynecol Endocrinol; 2022 Aug; 38(8):656-660. PubMed ID: 35850637
[No Abstract] [Full Text] [Related]
8. Subtype I (intrinsic) adenomyosis is an independent risk factor for dienogest-related serious unpredictable bleeding in patients with symptomatic adenomyosis.
Matsubara S; Kawaguchi R; Akinishi M; Nagayasu M; Iwai K; Niiro E; Yamada Y; Tanase Y; Kobayashi H
Sci Rep; 2019 Nov; 9(1):17654. PubMed ID: 31776404
[TBL] [Abstract][Full Text] [Related]
9. Prediction of the final menstrual period in women taking Dienogest using estradiol and follicle-stimulating hormone values: a case-control study.
Uehara M; Wada-Hiraike O; Koga K; Yamamoto N; Hirano M; Harada M; Hirota Y; Osuga Y
Endocr J; 2022 Dec; 69(12):1437-1445. PubMed ID: 36070964
[TBL] [Abstract][Full Text] [Related]
10. Risk factors for non-response and discontinuation of Dienogest in endometriosis patients: A cohort study.
Nirgianakis K; Vaineau C; Agliati L; McKinnon B; Gasparri ML; Mueller MD
Acta Obstet Gynecol Scand; 2021 Jan; 100(1):30-40. PubMed ID: 32767677
[TBL] [Abstract][Full Text] [Related]
11. Compare the Efficacy of Dienogest and the Levonorgestrel Intrauterine System in Women with Adenomyosis.
Guo W; Lin Y; Hu S; Shen Y
Clin Ther; 2023 Oct; 45(10):973-976. PubMed ID: 37599165
[TBL] [Abstract][Full Text] [Related]
12. A cohort study of the efficacy of the dienogest and the gonadotropin-releasing hormone agonist in women with adenomyosis and dysmenorrhea.
Ji M; Yuan M; Jiao X; Li Q; Huang Y; Li J; Wang G
Gynecol Endocrinol; 2022 Feb; 38(2):164-169. PubMed ID: 34749585
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of the efficacy and safety of dienogest in the treatment of painful symptoms in patients with adenomyosis: a randomized, double-blind, multicenter, placebo-controlled study.
Osuga Y; Fujimoto-Okabe H; Hagino A
Fertil Steril; 2017 Oct; 108(4):673-678. PubMed ID: 28911934
[TBL] [Abstract][Full Text] [Related]
14. Proposal for developing treatment algorithms of women with symptomatic adenomyosis: A single-center experience.
Kobayashi H; Imanaka S
J Obstet Gynaecol Res; 2021 Sep; 47(9):3257-3268. PubMed ID: 34155744
[TBL] [Abstract][Full Text] [Related]
15. Use of dienogest over 53 weeks for the treatment of endometriosis.
Sugimoto K; Nagata C; Hayashi H; Yanagida S; Okamoto A
J Obstet Gynaecol Res; 2015 Dec; 41(12):1921-6. PubMed ID: 26369271
[TBL] [Abstract][Full Text] [Related]
16. Uterine adenomyosis is an oligoclonal disorder associated with KRAS mutations.
Inoue S; Hirota Y; Ueno T; Fukui Y; Yoshida E; Hayashi T; Kojima S; Takeyama R; Hashimoto T; Kiyono T; Ikemura M; Taguchi A; Tanaka T; Tanaka Y; Sakata S; Takeuchi K; Muraoka A; Osuka S; Saito T; Oda K; Osuga Y; Terao Y; Kawazu M; Mano H
Nat Commun; 2019 Dec; 10(1):5785. PubMed ID: 31857578
[TBL] [Abstract][Full Text] [Related]
17. Effective salvage of acute massive uterine bleeding using intrauterine balloon tamponade in a uterine adenomyosis patient on dienogest.
Nishino K; Hayashi K; Chaya J; Kato N; Yamamuro O
J Obstet Gynaecol Res; 2013 Mar; 39(3):738-41. PubMed ID: 23003209
[TBL] [Abstract][Full Text] [Related]
18. Effectiveness of Dienogest for Treatment of Recurrent Endometriosis: Multicenter Data.
Lee JH; Song JY; Yi KW; Lee SR; Lee DY; Shin JH; Cho S; Seo SK; Kim SH
Reprod Sci; 2018 Oct; 25(10):1515-1522. PubMed ID: 29848190
[TBL] [Abstract][Full Text] [Related]
19. Uterine volume, menstrual patterns, and contraceptive outcomes in users of the levonorgestrel-releasing intrauterine system: A cohort study with a five-year follow-up.
Magalhaes J; Ferreira-Filho ES; Soares-Junior JM; Baracat EC
Eur J Obstet Gynecol Reprod Biol; 2022 Sep; 276():56-62. PubMed ID: 35809459
[TBL] [Abstract][Full Text] [Related]
20. Ultrasound findings in infertile women with endometriosis: evidence of concomitant uterine disorders.
Capezzuoli T; Vannuccini S; Fantappiè G; Orlandi G; Rizzello F; Coccia ME; Petraglia F
Gynecol Endocrinol; 2020 Sep; 36(9):808-812. PubMed ID: 32133885
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
